Expanding Product Portfolio Avinger is actively developing new applications for coronary artery disease treatment, opening opportunities to target cardiovascular hospitals and interventional cardiology centers seeking innovative intravascular systems.

Recent Funding Success With recent investments totaling over $20 million, including a public offering and strategic investments, Avinger is well-positioned to accelerate product development and expand its distribution network, presenting sales opportunities across clinical and hospital markets.

Market Entry Points The limited release of new devices like Tigereye ST at premier clinical centers indicates a focus on key opinion leaders and early adopters, which can facilitate broader adoption and drive sales through physician engagement and clinical evidence.

Integrated Tech Stack Utilizing advanced CRM and digital marketing tools suggests a data-driven approach to sales and marketing, enabling targeted outreach and personalized engagement with vascular specialists and hospital procurement teams.

Market Growth Potential With the underserved market for image-guided vascular devices, especially in coronary artery treatment, there is significant potential for expanding sales by emphasizing innovative, minimally invasive therapies to cardiology and peripheral vascular treatment facilities.